#Sweden #Stockholm #Eisai #Leqembi #BioArctic

Leqembi® Sales Skyrocket in Q2 2025

In a remarkable achievement, Leqembi®, a treatment developed for Alzheimer’s disease, recorded sales of 23.1 billion yen (approximately $165 million USD) during the second quarter of 2025. This substantial revenue milestone was announced by BioArctic AB’s partner, Eisai, alongside Biogen’s financial report for the same period. The sales figure represents a significant increase, with BioArctic receiving a royalty of SEK 162.5 million, which is an impressive 280% growth compared to the royalties earned in Q2 2024.

One notable factor contributing to this surge in sales was a strategic stockpiling effort in the Chinese market, amounting to about 5.3 billion yen, which was executed in anticipation of potential tariff implications. When excluding this stockpiling, total global sales for Leqembi amounted to approximately 17.8 billion yen, translating to royalty revenue of around SEK 125 million. This growth indicates a strong market acceptance and demand for Leqembi, further solidifying BioArctic and Eisai's position in the Alzheimer’s treatment sector.

BioArctic is set to release its complete report for Q2 2025 on August 28, 2025, at 08:00 a.m. CET, providing further insights into the performance of Leqembi and other developments within the company.

The Impact of Lecanemab

Lecanemab, marketed as Leqembi®, is a humanized monoclonal antibody designed to target aggregated forms of amyloid-beta, implicated in Alzheimer’s disease. This innovative treatment has gained approval in 46 countries, including major markets such as the U.S., Japan, and European Union nations, for patients diagnosed with Mild Cognitive Impairment (MCI) or mild dementia, which are early stages of Alzheimer's disease. Moreover, lecanemab is currently going through regulatory review in ten additional countries, highlighting its global potential.

Eisai has been leading a Phase 3 clinical study, AHEAD 3-45, focusing on individuals who show preclinical signs of Alzheimer’s, having completed recruitment in October 2024. This study is conducted in collaboration with Biogen and the Alzheimer's Clinical Trial Consortium, supported by funding from the National Institute on Aging. The research aims to bolster the capabilities of lecanemab as an early intervention for Alzheimer's disease, reinforcing BioArctic’s goal of developing effective treatments.

Long-term Collaboration Between BioArctic and Eisai

BioArctic and Eisai’s partnership dates back to 2005, centered on the development and commercialization of Alzheimer’s treatments. The most prominent agreements include the Development and Commercialization Agreement for the lecanemab antibody signed in 2007, and a secondary agreement for the antibody Leqembi® backup later signed in 2015. This collaboration reached a broader scope in 2014 when Eisai and Biogen entered a joint development and commercialization pact for lecanemab.

Under this partnership, Eisai manages clinical development, market approvals, and overall commercialization strategies for Alzheimer’s treatments, while BioArctic retains rights for commercialization in the Nordic region and is preparing to roll out Leqembi in those territories without incurring development costs.

About BioArctic

BioArctic AB (publ) is a biopharmaceutical company based in Sweden, focused on innovative therapies aimed at halting or reversing the progression of neurodegenerative conditions. Their flagship product, Leqembi®, represents a pioneering advancement in Alzheimer's disease management, demonstrating efficacy in delaying cognitive decline. With ongoing projects exploring treatments for Parkinson's disease and ALS, BioArctic is at the forefront of neurodegenerative research, utilizing proprietary technologies to enhance treatment effectiveness across various conditions.

For more details about BioArctic and its cutting-edge research, please visit www.bioarctic.com.